Abbott Laboratories ($ABT): What Does the Company Do? — Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Analysis of Abbott Laboratories (ABT) covering its stock price, earnings, outlook, market cap, dividends, related stocks, and headquarters. The company is a globally diversified healthcare conglomerate spanning medical devices, diagnostics, nutrition, and established pharmaceuticals. Diabetes management and cardiovascular device growth, together with consistent dividend returns, are the core variables for this representative healthcare name.
🏢 What kind of company is Abbott Laboratories?
Abbott Laboratories (ABT) is a globally diversified healthcare company headquartered in the US and founded in 1888. It operates across medical devices, diagnostics, nutrition, and established pharmaceuticals.
Its operations span medical devices for cardiovascular care, diabetes care (including the FreeStyle Libre continuous glucose monitor), neuromodulation, and structural heart; diagnostics covering core laboratory, rapid, molecular, and point-of-care testing; adult and pediatric nutrition; and established pharmaceuticals. It is a global leader in medical devices and diagnostics.
💰 How does Abbott Laboratories make money?
| Business Segment | Revenue Share | Description |
|---|---|---|
| Medical Devices | Core | Diabetes care (continuous glucose monitors), cardiovascular care, electrophysiology, and neuromodulation |
| Diagnostics | Key Growth Driver | Core laboratory, rapid, molecular, and point-of-care diagnostics |
| Nutrition | Diversification Pillar | Adult nutrition and pediatric nutrition products |
| Established Pharmaceuticals | Supplementary Business | Generics focused on emerging markets |
Recent annual revenue reflects steady growth within a diversified structure in which medical devices, diagnostics, nutrition, and established pharmaceuticals contribute in a balanced manner. Medical devices account for the largest share of revenue, with diabetes-care continuous glucose monitors and the cardiovascular and structural-heart businesses serving as key growth engines. The diagnostics segment is returning to its core diagnostic revenue base following the normalization of COVID-related tailwinds, while nutrition and established pharmaceuticals provide diversification and stability through emerging-market revenue exposure that helps buffer cyclical swings. Operating margins remain healthy, consistent with the profile of the medical devices business.
📐 Abbott Laboratories Market Cap and Company Scale
Market capitalization stands at $182.7B, with 115,000명 employees.
As a diversified healthcare company ranked among the leading global healthcare names by market cap, Abbott is benchmarked against MDT, SYK, BSX, and DHR in the medical devices and diagnostics space. Supported by stable free cash flow, it is a Dividend King that has delivered consecutive dividend increases over many years, while its diversified revenue mix across medical devices and diagnostics provides the foundation for its capital return program.
📈 Abbott Laboratories Outlook and Stock Performance
Global expansion of the FreeStyle Libre continuous glucose monitor and new product cycles in structural heart, neuromodulation, and electrophysiology devices are the core medium- to long-term growth drivers. In diagnostics, the return to core, molecular, and point-of-care diagnostics following the end of the COVID tailwind is serving as the recovery axis, while nutrition and established pharmaceuticals reinforce diversification through emerging-market revenue expansion. Near-term variables include FX, given the multinational revenue mix; litigation and reputational issues in nutrition; medical device new-product approval timelines; and the pace of diagnostics market normalization. All of these factors can drive volatility.
- Expansion of continuous glucose monitors, structural-heart products, and electrophysiology devices
- Core diagnostics growth following normalization in the diagnostics business
- Emerging-market revenue expansion in nutrition and established pharmaceuticals, paired with steady capital returns
⚔️ Abbott Laboratories Core Strengths and Risks
Abbott's diversified healthcare structure and long-term dividend returns are key strengths, while FX exposure, litigation issues in the nutrition segment, and medical device approval variables are the core risks.
💪 Core Strengths
⚠️ Core Risks
🔄 Abbott Laboratories Competitors and Related (Beneficiary) Stocks
Direct competitors include global medical device and diagnostics peers MDT (Medtronic), SYK (Stryker), BSX (Boston Scientific), and DHR (Danaher), which are benchmarked alongside Abbott. Related stocks include the diversified healthcare peer JNJ (Johnson & Johnson), the life sciences and diagnostics peer TMO (Thermo Fisher Scientific), and the medical devices peer BDX (Becton Dickinson). MDT, SYK, BSX, and DHR belong to the same medical devices and diagnostics peer category, while JNJ, TMO, and BDX fall along the diversified healthcare and life sciences adjacency axis.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| MDT | Medtronic Plc | $85.71 | -2.1% | $109.7B | 23.0 | 2.2 | 9.85% | 3.38% |
| SYK | Stryker Corp | $348.04 | -1.2% | $133.4B | 40.3 | 5.8 | 15.2% | 1.01% |
| BSX | Boston Scientific Corp | $46.00 | -0.1% | $68.4B | 18.7 | 2.6 | 14.83% | - |
| DHR | Danaher Corp | $196.17 | -0.2% | $137.9B | 34.8 | 2.6 | 7.61% | 0.73% |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $255.82 | -3.7% | $616.5B | 29.6 | 7.3 | 25.74% | 2.1% |
| TMO | Thermo Fisher Scientific Inc | $576.77 | +0.1% | $214.3B | 31.0 | 4.1 | 13.53% | 0.32% |
| BDX | Becton Dickinson & Co | $165.45 | -1.8% | $45.6B | 42.0 | 1.9 | 5.72% | 2.37% |
✅ Abbott Laboratories Investor Checklist
Key points to review when investing in Abbott include the medical device new-product cycle, the continuous glucose monitor expansion trajectory, diagnostics revenue normalization, and FX and nutrition-segment litigation variables, which are the key near- to mid-term drivers.
| Checklist | What to Confirm | Current Status |
|---|---|---|
| 🩸 Continuous Glucose Monitor | FreeStyle Libre revenue growth rate and emerging-market expansion | Steady expansion |
| 🫀 Medical Device New Products | Structural heart, electrophysiology, and neuromodulation approval timelines | Pipeline expansion phase |
| 💰 Dividends and Capital Return | Dividend increase trajectory and share buyback trends | Stable return flow |
| 🌍 FX and Emerging Markets | Multinational revenue translation and emerging-market growth trajectory | Worth monitoring |
During periods of dollar strength, the translation drag on multinational revenue can compress near-term revenue growth rates. Litigation and reputational issues in the nutrition segment, along with delays in medical device approvals, are near-term volatility drivers. Competition with MDT, SYK, BSX, and DHR in the medical devices market, as well as the pace of diagnostics revenue normalization, also affects the revenue trajectory.
Abbott is a globally diversified healthcare company with a stable revenue structure spanning medical devices, diagnostics, nutrition, and established pharmaceuticals, complemented by long-term dividend returns. Continuous glucose monitor expansion and the medical device new-product cycle are the key variables to watch, and dollar-cost averaging with a long-term perspective is recommended.
이 글은 2026년 5월 21일 기준 정보입니다.